Picture of Amplia Therapeutics logo

ATX — Amplia Therapeutics News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Amplia Therapeutics Says FDA Fast Track Designation For Narmafotinib In Advanced Pancreatic Cancer

Sept 20 (Reuters) - Amplia Therapeutics Ltd  ATX.AX :
    * FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED
PANCREATIC CANCER

Further company coverage:  ATX.AX

Recent news on Amplia Therapeutics

See all news